Outcomes of Argatroban Treatment in Patients With Atherothrombotic Stroke | Zendy

Tomoki Wada | Zendy; Hideo Yasunaga | Zendy; Hiromasa Horiguchi | Zendy; Takehiro Matsubara | Zendy; Kiyohide Fushimi | Zendy; Susumu Nakajima | Zendy; Naoki Yahagi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Outcomes of Argatroban Treatment in Patients With Atherothrombotic Stroke

Author(s) -

Tomoki Wada,

Hideo Yasunaga,

Hiromasa Horiguchi,

Takehiro Matsubara,

Kiyohide Fushimi,

Susumu Nakajima,

Naoki Yahagi

Publication year - 2015

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.115.011250

Subject(s) - argatroban , medicine , modified rankin scale , stroke (engine) , odds ratio , propensity score matching , retrospective cohort study , confidence interval , ischemic stroke , thrombin , mechanical engineering , platelet , ischemia , engineering

Argatroban, a selective thrombin inhibitor, is recommended for the use in patients with atherothrombotic stroke by the Japanese Guidelines for the Management of Patients with Acute Ischemic Stroke. We performed a nationwide Japanese study to investigate whether argatroban improved early stroke outcomes in patients with acute atherothrombotic stroke.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research